Lung Cancer Drug Lincoln NE

Maintenance therapy with the drug pemetrexed improves the survival of people with non-small-cell lung cancer whose disease has not progressed after chemotherapy in Lincoln, a new study has found.Nearly 90 percent of all people who die from lung cancer have non-small-cell tumors. At the time the cancer is discovered, it's considered advanced about 40 percent of the time, according to background information in a news release from The Lancet, which is publishing the study.

Douglas Dean Dalke, MD
(402) 465-4545
4545 R St Ste 100
Lincoln, NE
Specialties
Gastroenterology
Gender
Male
Education
Medical School: Univ Of Ne Coll Of Med, Omaha Ne 68198
Graduation Year: 1982

Data Provided by:
Andrew David Coen, MD
(402) 465-4545
4545 R St Ste 101
Lincoln, NE
Specialties
Gastroenterology
Gender
Male
Education
Medical School: Univ Of Ne Coll Of Med, Omaha Ne 68198
Graduation Year: 1999

Data Provided by:
Gary William Varilek, MD
(402) 465-4545
4545 R St Ste 100
Lincoln, NE
Specialties
Gastroenterology
Gender
Male
Education
Medical School: Creighton Univ Sch Of Med, Omaha Ne 68178
Graduation Year: 1983

Data Provided by:
Mark Gregory Griffin, MD
(402) 465-4545
4545 R St Ste 100
Lincoln, NE
Specialties
Gastroenterology
Gender
Male
Education
Medical School: Univ Of Mo-Kansas City Sch Of Med, Kansas City Mo 64108
Graduation Year: 1988

Data Provided by:
Dr.Mark Griffin
4545 R St # 100
Lincoln, NE
Gender
M
Speciality
Gastroenterologist
General Information
Hosptital: St. Elizabeths
RateMD Rating
4.7, out of 5 based on 3, reviews.

Data Provided by:
Paul Floyd Petersen, MD
(402) 465-4545
4545 R St Ste 100
Lincoln, NE
Specialties
Gastroenterology
Gender
Male
Education
Medical School: Univ Of Ne Coll Of Med, Omaha Ne 68198
Graduation Year: 1992

Data Provided by:
David Richard Dyke, MD
(402) 465-4545
4545 R St Ste 100
Lincoln, NE
Specialties
Gastroenterology
Gender
Male
Education
Medical School: Univ Of Ne Coll Of Med, Omaha Ne 68198
Graduation Year: 1966

Data Provided by:
Dr.David Dyke
(402) 465-4545
4545 R St # 100
Lincoln, NE
Gender
M
Education
Medical School: Univ Of Ne Coll Of Med
Year of Graduation: 1966
Speciality
Gastroenterologist
General Information
Accepting New Patients: Yes
RateMD Rating
4.8, out of 5 based on 2, reviews.

Data Provided by:
Clark William Antonson, MD
(402) 465-4545
4545 R St Ste 100
Lincoln, NE
Specialties
Gastroenterology
Gender
Male
Education
Medical School: Univ Of Ne Coll Of Med, Omaha Ne 68198
Graduation Year: 1985

Data Provided by:
Richard Martin Pitsch, MD
(402) 483-7825
4740 A St
Lincoln, NE
Gender
Male
Education
Medical School: Univ Of Ne Coll Of Med, Omaha Ne 68198
Graduation Year: 1976
Hospital
Hospital: Lincoln General Hospital, Lincoln, Ne
Group Practice: Lincoln Surgical Group

Data Provided by:
Data Provided by:

Lung Cancer Drug

Provided By:

SATURDAY, Sept. 19 (HealthDay News) -- Maintenance therapy with the drug pemetrexed improves the survival of people with non-small-cell lung cancer whose disease has not progressed after chemotherapy, a new study has found.Nearly 90 percent of all people who die from lung cancer have non-small-cell tumors. At the time the cancer is discovered, it's considered advanced about 40 percent of the time, according to background information in a news release from The Lancet, which is publishing the study. Chemotherapy reduces the tumors in just 40 percent of advanced cases, it said.

The phase 3 study included 663 people in 20 countries who had an advanced stage of the cancer but no disease progression after four cycles of platinum-based chemotherapy. They were randomly selected to be given pemetrexed or a placebo in 21-day cycles.

The cancers did not progress for 4.3 months, on average, in people in the pemetrexed group, compared with 2.6 months in the placebo group, the study found. People given pemetrexed survived an average of 13.4 months, compared with 10.6 months for those given the placebo.

That means that those in the pemetrexed group had a 50 percent reduction in the risk for disease progression or death and a 21 percent reduction in the risk of death only, the researchers said.

Drug-related toxic effects caused discontinuation of treatment in 5 percent of the pemetrexed group and 4 percent of the placebo group. No deaths were found to be related to pemetrexed, according to the study.

"Pemetrexed maintenance therapy is well tolerated and offers significantly improved progression-free and overall survival compared with placebo, making it a new treatment option for patients with advanced non-squamous, non-small-cell lung cancer who do not progress after initial induction therapy," Dr. Chandra Belani, of the Penn State Hershey Cancer Institute, and her colleagues concluded.

The study, which appears online and in an upcoming print issue of The Lancet, was released Sept. 19 to coincide with the European Cancer Organization meeting.

Dr. Thomas Stinchcombe of the Lineberger Comprehensive Cancer Center at the University of North Carolina, and Dr. Howard West, of the Swedish Cancer Institute in Seattle, wrote in an accompanying editorial that the use of pemetrexed as maintenance therapy "merits being considered as a strong option, reflected by the recent approval of pemetrexed in this setting by the European Medicines Agency and the U.S. Food and Drug Administration."

More information

The American Cancer Society has more about non-small-cell lung cancer.

SOURCE: The Lancet, news release, Sept. 19, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com